Akeega™ (niraparib/abiraterone) – New drug approval
August 11, 2023 - Janssen announced the FDA approval of Akeega (niraparib/abiraterone), for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
Download PDF
